Janux Therapeutics Future Growth
Future criteria checks 2/6
Janux Therapeutics's earnings are forecast to decline at 26% per annum while its annual revenue is expected to grow at 51.1% per year. EPS is expected to decline by 20.2% per annum. Return on equity is forecast to be -18.5% in 3 years.
Key information
-26.0%
Earnings growth rate
-20.2%
EPS growth rate
| Biotechs earnings growth | 27.6% |
| Revenue growth rate | 51.1% |
| Future return on equity | -18.5% |
| Analyst coverage | Good |
| Last updated | 11 Dec 2024 |
Recent future growth updates
Recent updates
Janux Therapeutics: Hype Breeds Volatility, And That Should Give You Pause
Dec 03Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business
Oct 01
Janux Therapeutics: Buoyed By Buyout Speculation
Sep 01Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation
Jul 01Janux Therapeutics: A Prime Target In Cancer Care's M&A Game
Apr 11Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024
Feb 27Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth
Feb 24Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?
Dec 29Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans
Nov 04We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely
Jul 20A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)
May 23Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation
Feb 09We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth
Oct 19Janux Therapeutics GAAP EPS of -$0.41, revenue of $2.37M
Aug 09We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth
Jun 05Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans
Feb 19Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation
Nov 03Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 11 | -162 | -192 | -93 | 11 |
| 12/31/2025 | 6 | -117 | -144 | -71 | 11 |
| 12/31/2024 | 11 | -73 | -52 | -43 | 10 |
| 9/30/2024 | 13 | -61 | -38 | -37 | N/A |
| 6/30/2024 | 15 | -44 | -48 | -46 | N/A |
| 3/31/2024 | 7 | -56 | -53 | -52 | N/A |
| 12/31/2023 | 8 | -58 | -52 | -51 | N/A |
| 9/30/2023 | 8 | -63 | -56 | -53 | N/A |
| 6/30/2023 | 8 | -68 | -60 | -54 | N/A |
| 3/31/2023 | 9 | -67 | -51 | -45 | N/A |
| 12/31/2022 | 9 | -63 | -49 | -43 | N/A |
| 9/30/2022 | 7 | -60 | -47 | -41 | N/A |
| 6/30/2022 | 7 | -54 | -37 | -34 | N/A |
| 3/31/2022 | 5 | -44 | -36 | -34 | N/A |
| 12/31/2021 | 4 | -33 | -18 | -17 | N/A |
| 9/30/2021 | 2 | -21 | -8 | -8 | N/A |
| 6/30/2021 | 1 | -11 | -4 | -3 | N/A |
| 3/31/2021 | 0 | -8 | 2 | 2 | N/A |
| 12/31/2020 | N/A | -7 | -4 | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: JANX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: JANX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: JANX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: JANX's revenue (51.1% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: JANX's revenue (51.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: JANX is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 16:15 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Janux Therapeutics, Inc. is covered by 13 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Kaveri Pohlman | BTIG |
| Justin Zelin | BTIG |